Overview

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2009-07-14
Target enrollment:
Participant gender:
Summary
Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Spanish Breast Cancer Research Group
Collaborator:
Schering-Plough
Treatments:
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Trastuzumab